CAH Quote, Financials, Valuation and Earnings

Cencora has a net margin of 0.8% compared to Cardinal Health's net margin of 0%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 157.14%.

Cardinal Health has a consensus price target of $132.14, signalling upside risk potential of 3.37%. On the other hand Cencora has an analysts' consensus of $267.88 which suggests that it could grow by 9.31%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.628, which suggesting that the stock is 37.189% less volatile than S&P 500. In comparison Cencora has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.344%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.58%. Cencora offers a yield of 0.85% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are smaller than Cencora quarterly revenues of $79.1B. Cardinal Health's net income of $416M is higher than Cencora's net income of $3.4M. Notably, Cardinal Health's price-to-earnings ratio is 24.87x while Cencora's PE ratio is 32.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.14x versus 0.17x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 0.8% compared to Cardinal Health's net margin of 8.28%. Cardinal Health's return on equity of -- beat Globus Medical's return on equity of 2.27%.

Cardinal Health has a consensus price target of $132.14, signalling upside risk potential of 3.37%. On the other hand Globus Medical has an analysts' consensus of $97.85 which suggests that it could grow by 5.88%. Given that Globus Medical has higher upside potential than Cardinal Health, analysts believe Globus Medical is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.628, which suggesting that the stock is 37.189% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.58%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are larger than Globus Medical quarterly revenues of $625.7M. Cardinal Health's net income of $416M is higher than Globus Medical's net income of $51.8M. Notably, Cardinal Health's price-to-earnings ratio is 24.87x while Globus Medical's PE ratio is 137.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.14x versus 5.11x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.8% compared to Cardinal Health's net margin of 0.26%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $132.14, signalling upside risk potential of 3.37%. On the other hand McKesson has an analysts' consensus of $650.81 which suggests that it could grow by 11.05%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.628, which suggesting that the stock is 37.189% less volatile than S&P 500. In comparison McKesson has a beta of 0.521, suggesting its less volatile than the S&P 500 by 47.898%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.58%. McKesson offers a yield of 0.45% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are smaller than McKesson quarterly revenues of $93.7B. Cardinal Health's net income of $416M is higher than McKesson's net income of $241M. Notably, Cardinal Health's price-to-earnings ratio is 24.87x while McKesson's PE ratio is 30.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.14x versus 0.23x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 0.8% compared to Cardinal Health's net margin of 25.43%. Cardinal Health's return on equity of -- beat ResMed's return on equity of 23.76%.

Cardinal Health has a consensus price target of $132.14, signalling upside risk potential of 3.37%. On the other hand ResMed has an analysts' consensus of $258.40 which suggests that it could grow by 4.28%. Given that ResMed has higher upside potential than Cardinal Health, analysts believe ResMed is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.628, which suggesting that the stock is 37.189% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.58%. ResMed offers a yield of 0.82% to investors and pays a quarterly dividend of $0.53 per share. Cardinal Health pays 58.57% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $52.3B, which are larger than ResMed quarterly revenues of $1.2B. Cardinal Health's net income of $416M is higher than ResMed's net income of $311.4M. Notably, Cardinal Health's price-to-earnings ratio is 24.87x while ResMed's PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.14x versus 7.60x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.